Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

No Link Found Between LCIS and Local Recurrence

February 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

BOSTON-Neither the presence nor the extent of lobular carcinoma in situ (LCIS) is related to risk of local recurrence in patients with invasive breast cancer treated with conservative surgery and radiotherapy, a retrospective study from the Joint Center for Radiation Therapy has shown.

BOSTON—Neither the presence nor the extent of lobular carcinoma insitu (LCIS) is related to risk of local recurrence in patients with invasivebreast cancer treated with conservative surgery and radiotherapy, a retrospectivestudy from the Joint Center for Radiation Therapy has shown.

"This is very different from the situation with associated DCIS,"Stuart Schnitt, MD, said at a general session. Joint Center data show thatinfiltrating ductal carcinoma with a large amount of associated DCIS hasa five-year local recurrence rate of 24% vs 6% when there is little orno DCIS.

The LCIS study included 858 patients with clinical stage I or II infiltratingductal carcinoma (782 patients), infiltrating lobular carcinoma (44 patients),or infiltrating carcinoma with mixed ductal and lobular features (32 patients),treated with conservative surgery and radiotherapy.

Overall, neither local recurrence nor the incidence of distant failurewas related to histologic type. In terms of LCIS, 4% of patients with infiltratingductal cancer had associated LCIS. Not surprisingly, the vast majority(93%) of patients with infiltrating lobular carcinoma had associated LCIS.Of the patients with mixed ductal/lobular features, 59% had associatedLCIS.

Other prognostic factors for local recurrence were equally distributedamong the three groups and among those with and without LCIS. The mostimportant prognostic factor, margin status, was unknown in most patients.

The investigators then looked at the 10-year crude rate of local recurrenceamong patients with and without LCIS. Patients with infiltrating ductalcarcinoma and no LCIS had a local recurrence rate of 14% vs 10% for thosefew patients in whom LCIS was present. Among infiltrating lobular carcinomas,there were no local recurrences in the three patients without LCIS, andfive (12%) among the patients with LCIS.

For patients with mixed features, local recurrence was 15% with no LCIS,and 16% with LCIS. None of these differences were significant. Similarly,the extent of LCIS was not associated with the risk of local recurrencein any group. Based on these results, Dr. Schnitt suggests that the presenceof associated LCIS should not influence local management of infiltratingductal, lobular, or mixed carcinoma.

Articles in this issue

NCI Launches Trial of High-Dose Chemo for Advanced Ovarian Cancer
Brachytherapy to Tumor Bed After Lumpectomy a Possible Alternative to External Beam Therapy
Breast Conservation Is Contraindicated in Less Than 25% of Early-Stage Patients
'More May Be Less' in Metastatic Cervical Cancer
At 10 Years, DCIS Patients' Risk of Breast Cancer Death Is Very Low
Tumor Cells in Marrow May Better Predict Metastases Than Axillary Node Dissection
Survey Finds 122 New Anti-HIV Medicines Currently Being Tested
Delaying Radiotherapy to Allow Adjuvant Chemotherapy Not Shown to Increase Ipsilateral Recurrence Risk
President Clinton Unveils National AIDS Policy
Mammotomy May Reduce Biopsy Sampling Errors
Ultrasound Advances May Expand Role in Treatment Planning
Bills to Regulate Managed Care Are Introduced
NIH Consensus Development Statement Sparks Rancor
Breast Cancer Patients May Overestimate the Benefits of Adjuvant Chemotherapy
Letrozole Superior to Progestin as Second-Line Postmenopausal Advanced Breast Cancer Therapy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

Virginia Kaklamani, MD, DSc;Giorgi Dzagnidze;Nicoleta Zenovia Antone;Anu Thummala;Mikheil Janjalia;Patricia Santi;Carlos Barrios;Mehmet Ali Nahit Sendur;Xiaoling Zhang;Angela Gambioli;Manuel Dominguez;Kathy Puyana Theall;Tomer Wasserman;William J. Gradishar, MD
June 12th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

Ariana Pelosci
June 2nd 2025
Article

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Gina Mauro
June 1st 2025
Article

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.


Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC

Russ Conroy
June 1st 2025
Article

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Related Content

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

Virginia Kaklamani, MD, DSc;Giorgi Dzagnidze;Nicoleta Zenovia Antone;Anu Thummala;Mikheil Janjalia;Patricia Santi;Carlos Barrios;Mehmet Ali Nahit Sendur;Xiaoling Zhang;Angela Gambioli;Manuel Dominguez;Kathy Puyana Theall;Tomer Wasserman;William J. Gradishar, MD
June 12th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

Ariana Pelosci
June 2nd 2025
Article

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Gina Mauro
June 1st 2025
Article

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.


Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC

Russ Conroy
June 1st 2025
Article

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.